Form 4: Foghorn Therapeutics Director Douglas G. Cole Acquires 16,000 Stock Options

Director Douglas G. Cole acquired 16,000 stock options in Foghorn Therapeutics Inc. on June 26, 2024, at an exercise price of $5.52.

Summary

• On June 26, 2024, Douglas G. Cole, a director of Foghorn Therapeutics Inc., acquired 16,000 stock options.
• The exercise price for these options is $5.52.
• The options become exercisable on June 26, 2025, and expire on June 25, 2034.
• Following the transaction, Mr. Cole beneficially owns 16,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director. While insider buying can be seen as positive, option grants are part of compensation and don't necessarily indicate strong bullish sentiment.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders reporting transactions in their company's securities. It provides transparency to the market regarding insider activity.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.

Key Dates